By Stephen Nakrosis

Nurix Therapeutics on Wednesday said the Food and Drug Administration placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies.

Nurix said NX-2127 is currently being evaluated in patients with relapsed or refractory B cell malignancies.

The biopharmaceutical company said the hold comes after it informed the FDA it intends transition to an improved manufacturing process. None of the company's other drug programs are affected by the NX-2127 manufacturing process improvement, it said.

Screening and enrollment of new study participants has been paused, but patients currently enrolled may continue to receive treatment in accordance with the ongoing study protocol, Nurix said. The company also said it is working with the FDA to resolve the partial clinical hold as soon as possible.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 01, 2023 17:01 ET (21:01 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Nurix Therapeutics (NASDAQ:NRIX)
過去 株価チャート
から 4 2024 まで 5 2024 Nurix Therapeuticsのチャートをもっと見るにはこちらをクリック
Nurix Therapeutics (NASDAQ:NRIX)
過去 株価チャート
から 5 2023 まで 5 2024 Nurix Therapeuticsのチャートをもっと見るにはこちらをクリック